Abstract

Results of both monkey and human trials have highlighted the difficulties in achieving vaccine protection against SIV and HIV. Persistent, recombinant herpes viruses are being used in monkeys to try to match the degree of protection that can be achieved with live attenuated strains of SIV. Results to date have been promising but the absence of anti-Env antibody responses from the recombinant herpes viruses has been a glaring deficiency. The proposed experiments will overcome this deficiency and allow full testing of the promise of this approach.

Public Health Relevance

The proposed experiments will allow a greater appreciation of the potential for recombinant herpes viruses in particular, and persistent vectors in general, for their capacity to provide protection against AIDS virus exposure. If shown to be significantly better than other vaccine approaches, it will shape the emphasis for ongoing preclinical vaccine discovery research.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI063928-06A1
Application #
8462347
Study Section
HIV/AIDS Vaccines Study Section (VACC)
Program Officer
Pensiero, Michael N
Project Start
2004-12-01
Project End
2013-05-31
Budget Start
2012-12-01
Budget End
2013-05-31
Support Year
6
Fiscal Year
2013
Total Cost
$240,000
Indirect Cost
$102,857

  Institution

Name
Harvard University
Department
Veterinary Sciences
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115

  Publications

Bischof, Georg F; Magnani, Diogo M; Ricciardi, Michael et al. (2017) Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys. J Virol 91:
Hahn, Alexander S; Desrosiers, Ronald C (2014) Binding of the Kaposi's sarcoma-associated herpesvirus to the ephrin binding surface of the EphA2 receptor and its inhibition by a small molecule. J Virol 88:8724-34
Hahn, Alexander S; Desrosiers, Ronald C (2013) Rhesus monkey rhadinovirus uses eph family receptors for entry into B cells and endothelial cells but not fibroblasts. PLoS Pathog 9:e1003360
Shin, Young C; Desrosiers, Ronald C (2011) Rhesus monkey rhadinovirus ORF57 induces gH and gL glycoprotein expression through posttranscriptional accumulation of target mRNAs. J Virol 85:7810-7
Bilello, John P; Manrique, Julieta M; Shin, Young C et al. (2011) Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus. J Virol 85:12708-20
Shin, Young C; Jones, Leandro R; Manrique, Julieta et al. (2010) Glycoprotein gene sequence variation in rhesus monkey rhadinovirus. Virology 400:175-86
Bilello, John P; Morgan, Jennifer S; Desrosiers, Ronald C (2008) Extreme dependence of gH and gL expression on ORF57 and association with highly unusual codon usage in rhesus monkey rhadinovirus. J Virol 82:7231-7
Schafer, Alexandra; Cai, Xuezhong; Bilello, John P et al. (2007) Cloning and analysis of microRNAs encoded by the primate gamma-herpesvirus rhesus monkey rhadinovirus. Virology 364:21-7
Cai, Xuezhong; Schafer, Alexandra; Lu, Shihua et al. (2006) Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2:e23
Bilello, John P; Lang, Sabine M; Wang, Fred et al. (2006) Infection and persistence of rhesus monkey rhadinovirus in immortalized B-cell lines. J Virol 80:3644-9

Showing the most recent 10 out of 11 publications